Chemistree Technology Inc OTCMKTS: CHMJF Acquires Ownership Stake in The Physician’s Choice CBD LLC


Chemistree Technology Inc OTCMKTS: CHMJF is an investment company dedicated to the U.S. cannabis sector, endeavoring to provide turn-key solutions for the regulated cannabis industry. The Company’s corporate strategy is to acquire and develop vertically integrated cannabis assets, leveraging management’s decades of expertise in the cannabis industry and corporate finance to own and operate licensed cultivation, processing, distribution and retail facilities.

Chemistree Technology Inc OTCMKTS: CHMJF On April 29, 2019 announce that the Company has entered into a funding agreement with The Physician’s Choice CBD LLC of Phoenix, Arizona.

The Physician’s Choice CBD (“PCCBD”) is dedicated to research, development, and utilization of the highest quality of hemp-derived cannabidiol (CBD) combined with well-studied and effective supplements specific to help regulate and support various symptoms. The integration of extensive physician clinical experience combined with exhaustive expertise in the cannabis industry has led to the creation of The Physician’s Choice CBD.

Established in 2018, PCCBD has already developed a suite of nine full spectrum CBD from Hemp products ranging from pain/inflammation management to sleep and wellness supplements. In it’s first quarter of sales ended January 2019, the company booked approximately $150,000 in sales. The Physicians Choice CBD offers complete wholesale programs as well as a referral program compensating healthcare providers on purchases from codes provided to their patients.

With over 15 years in private practice, Dr. Julian Grove, M.D. and Dr. Peter Kubitz, D.O., have experienced first-hand the difficulties and complex dilemmas in treating patients suffering from chronic pain. From a medical management perspective, the treatment of pain is at a crossroads as for the last two decades, the intersection of various forms of pain medications and the prominent and real consequences of their use has created a globally recognized problem. The side effects, end-organ damage, and the potential for addiction and abuse are global concerns. As providers treating patients with complex pain daily, the doctors offer patients a myriad of different treatments including physical therapy, interventional therapies (nerve blocks, spinal cord stimulation), and complementary treatments (chiropractic, naturopathic medicine, massage, acupuncture, psychological support). Unfortunately, many times, this is not enough.

Dr. Grove stated, “Managing various pain syndromes with medications that do not exacerbate severe medical conditions and behavioral risk factors is an ongoing challenge for medical professionals. This has been a driving force in the development of a product line of cannabidiol products, aiding in the management of specific pain syndromes and improve a sense of well-being.”

Chemistree president Karl Kottmeier commented “This investment in The Physician’s Choice CBD is a great opportunity for Chemistree. Dr. Grove and Dr. Kubitz are board certified practicing physicians with training at Harvard and the Mayo Clinic, specializing in pain management. Their collective education and practical experience is industry-leading and their commitment to the health of their patients and to developing real solutions to pain management with cannabidiol-based supplements is truly inspiring. The investment we are making into PCCBD gives us exposure to an entirely new industry and we are excited to assist whereever we can to see PCCBD continue to grow its sales and product offerings into a multi-state success.
Chemistree Technology Inc OTCMKTS: CHMJF On April 18, 2019 provide shareholders with an update on the Company’s Washington State assets and its Desert Hot Springs, California cultivation facility development.

Newly appointed Chief Cannabis Officer Sheldon Aberman commented, “I am really pleased with the team at Sugarleaf Washington. With the full support of Chemistree as landlord and turnkey equipment provider, this group of people continue to do a tremendous job in restoring Sugarleaf to its previous place in the Washington market for flower and pre-rolled products as well as introducing new exciting products to the market. We are confident that this trajectory of success will continue and that Sugarleaf’s loyal retail customers will continue to enjoy the high quality products and welcome the new offerings as they are rolled out.”

Chemistree is also actively advancing its 9.55 acre Desert Hot Springs land package. “Our design team is currently in the process of finalizing plans for our two 64,000 square foot greenhouses and 40,000 square foot manufacturing and distribution facility for submission to the city of Desert Hot Springs. We expect city review to be completed by the third quarter of this year. The project continues to track on schedule with completion targeted for the first quarter of 2020.” said Aberman.